Amgen Inc vs. Inhibikase Therapeutics, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| AMGN | IKT | |
|---|---|---|
| Market Cap | $208.49 billion | $320.93 million |
| Revenue (TTM) | $38.09 billion | $3.72 million |
| Net Income (TTM) | $8.74 billion | $-60,637,002 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | IKT | |
|---|---|---|
| P/E Ratio | 24.35 | — |
| Price / Book | 17.84 | 2.09 |
| Price / Sales | 5.47 | 86.39 |
AMGN and IKT split the valuation factors evenly.
Profitability
| AMGN | IKT | |
|---|---|---|
| Net Margin | 22.95% | -1632.18% |
| Return on Equity | 74.80% | -39.55% |
AMGN leads on 2 of 2 profitability factors.
Dividend
| AMGN | IKT | |
|---|---|---|
| Dividend Yield | 2.57% | — |
| Payout Ratio | 62.61 | — |
AMGN and IKT split the dividend factors evenly.
Risk & Sentiment
| AMGN | IKT | |
|---|---|---|
| Short Interest | 1.66% | 0.02% |
IKT leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, IKT overview, IKT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.